Metformin inhibition of neuroblastoma cell proliferation is differently modulated by cell differentiation induced by retinoic acid or overexpression of NDM29 non-coding RNA

Delfina Costa, Arianna Gigoni, Roberto Wu¨rth, Ranieri Cancedda, Tullio Florio, Aldo Pagano

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Background: Metformin is a widely used oral hypoglycemizing agent recently proposed as potential anti-cancer drug. In this study we report the antiproliferative effect of metformin treatment in a high risk neuroblastoma cell model, focusing on possible effects associated to different levels of differentiation and/or tumor initiating potential.Methods: Antiproliferative and cytotoxic effects of metformin were tested in human SKNBE2 and SH-SY5Y neuroblastoma cell lines and in SKNBE2 cells in which differentiation is induced by retinoic acid treatment or stable overexpression of NDM29 non-coding RNA, both conditions characterized by a neuron-like differentiated phenotype.Results: We found that metformin significantly inhibits the proliferation of NB cells, an effect that correlates with the inhibition of Akt, while AMPK activity resulted unchanged. Notably, metformin effects were modulated in a different ways by differentiating stimuli, being abolished after retinoic acid treatment but potentiated by overexpression of NDM29.Conclusion: These data suggest the efficacy of metformin as neuroblastoma anticancer agent, and support the requirement of further studies on the possible role of the differentiation status on the antiproliferative effects of this drug.

Original languageEnglish
Article number59
JournalCancer Cell International
Volume14
Issue number1
Publication statusPublished - Jul 2 2014

Fingerprint

Untranslated RNA
Metformin
Tretinoin
Neuroblastoma
Cell Differentiation
Cell Proliferation
AMP-Activated Protein Kinases
Pharmaceutical Preparations
Antineoplastic Agents
Neoplasms
Phenotype
Neurons
Cell Line

Keywords

  • Anti-cancer therapy
  • Differentiation
  • Metformin
  • NDM29 ncRNA
  • Neuroblastoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Genetics

Cite this

Metformin inhibition of neuroblastoma cell proliferation is differently modulated by cell differentiation induced by retinoic acid or overexpression of NDM29 non-coding RNA. / Costa, Delfina; Gigoni, Arianna; Wu¨rth, Roberto; Cancedda, Ranieri; Florio, Tullio; Pagano, Aldo.

In: Cancer Cell International, Vol. 14, No. 1, 59, 02.07.2014.

Research output: Contribution to journalArticle

@article{73b913cb3e35477f91923fb659dee5c0,
title = "Metformin inhibition of neuroblastoma cell proliferation is differently modulated by cell differentiation induced by retinoic acid or overexpression of NDM29 non-coding RNA",
abstract = "Background: Metformin is a widely used oral hypoglycemizing agent recently proposed as potential anti-cancer drug. In this study we report the antiproliferative effect of metformin treatment in a high risk neuroblastoma cell model, focusing on possible effects associated to different levels of differentiation and/or tumor initiating potential.Methods: Antiproliferative and cytotoxic effects of metformin were tested in human SKNBE2 and SH-SY5Y neuroblastoma cell lines and in SKNBE2 cells in which differentiation is induced by retinoic acid treatment or stable overexpression of NDM29 non-coding RNA, both conditions characterized by a neuron-like differentiated phenotype.Results: We found that metformin significantly inhibits the proliferation of NB cells, an effect that correlates with the inhibition of Akt, while AMPK activity resulted unchanged. Notably, metformin effects were modulated in a different ways by differentiating stimuli, being abolished after retinoic acid treatment but potentiated by overexpression of NDM29.Conclusion: These data suggest the efficacy of metformin as neuroblastoma anticancer agent, and support the requirement of further studies on the possible role of the differentiation status on the antiproliferative effects of this drug.",
keywords = "Anti-cancer therapy, Differentiation, Metformin, NDM29 ncRNA, Neuroblastoma",
author = "Delfina Costa and Arianna Gigoni and Roberto Wu¨rth and Ranieri Cancedda and Tullio Florio and Aldo Pagano",
year = "2014",
month = "7",
day = "2",
language = "English",
volume = "14",
journal = "Cancer Cell International",
issn = "1475-2867",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Metformin inhibition of neuroblastoma cell proliferation is differently modulated by cell differentiation induced by retinoic acid or overexpression of NDM29 non-coding RNA

AU - Costa, Delfina

AU - Gigoni, Arianna

AU - Wu¨rth, Roberto

AU - Cancedda, Ranieri

AU - Florio, Tullio

AU - Pagano, Aldo

PY - 2014/7/2

Y1 - 2014/7/2

N2 - Background: Metformin is a widely used oral hypoglycemizing agent recently proposed as potential anti-cancer drug. In this study we report the antiproliferative effect of metformin treatment in a high risk neuroblastoma cell model, focusing on possible effects associated to different levels of differentiation and/or tumor initiating potential.Methods: Antiproliferative and cytotoxic effects of metformin were tested in human SKNBE2 and SH-SY5Y neuroblastoma cell lines and in SKNBE2 cells in which differentiation is induced by retinoic acid treatment or stable overexpression of NDM29 non-coding RNA, both conditions characterized by a neuron-like differentiated phenotype.Results: We found that metformin significantly inhibits the proliferation of NB cells, an effect that correlates with the inhibition of Akt, while AMPK activity resulted unchanged. Notably, metformin effects were modulated in a different ways by differentiating stimuli, being abolished after retinoic acid treatment but potentiated by overexpression of NDM29.Conclusion: These data suggest the efficacy of metformin as neuroblastoma anticancer agent, and support the requirement of further studies on the possible role of the differentiation status on the antiproliferative effects of this drug.

AB - Background: Metformin is a widely used oral hypoglycemizing agent recently proposed as potential anti-cancer drug. In this study we report the antiproliferative effect of metformin treatment in a high risk neuroblastoma cell model, focusing on possible effects associated to different levels of differentiation and/or tumor initiating potential.Methods: Antiproliferative and cytotoxic effects of metformin were tested in human SKNBE2 and SH-SY5Y neuroblastoma cell lines and in SKNBE2 cells in which differentiation is induced by retinoic acid treatment or stable overexpression of NDM29 non-coding RNA, both conditions characterized by a neuron-like differentiated phenotype.Results: We found that metformin significantly inhibits the proliferation of NB cells, an effect that correlates with the inhibition of Akt, while AMPK activity resulted unchanged. Notably, metformin effects were modulated in a different ways by differentiating stimuli, being abolished after retinoic acid treatment but potentiated by overexpression of NDM29.Conclusion: These data suggest the efficacy of metformin as neuroblastoma anticancer agent, and support the requirement of further studies on the possible role of the differentiation status on the antiproliferative effects of this drug.

KW - Anti-cancer therapy

KW - Differentiation

KW - Metformin

KW - NDM29 ncRNA

KW - Neuroblastoma

UR - http://www.scopus.com/inward/record.url?scp=84903406795&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903406795&partnerID=8YFLogxK

M3 - Article

VL - 14

JO - Cancer Cell International

JF - Cancer Cell International

SN - 1475-2867

IS - 1

M1 - 59

ER -